US Patent:
20090130123, May 21, 2009
Inventors:
Erol Fikrig - Guilford CT, US
Hannah Gould - New Haven CT, US
Raymond A. Koski - Old Lyme CT, US
Michel Ledizet - Woodbridge CT, US
Wayne A. Marasco - Wellesley MA, US
Jianhua Sui - Boston MA, US
International Classification:
A61K 39/395
C07K 16/18
C12N 5/06
C12N 15/11
C12N 15/00
C12P 21/04
A01K 67/027
A01H 5/00
A61K 31/7088
C12Q 1/70
US Classification:
4241591, 5303871, 5303873, 435339, 536 2353, 4353201, 435 696, 800298, 800 13, 514 44, 800 3, 435 5
Abstract:
The present invention relates to anti-West Nile virus E protein (WNE) antibodies, including human antibodies, and antigen-binding portions thereof. In particular, the invention relates to such antibodies and portions that prevent, inhibit, or treat a flavivirus infection, including a West Nile Virus infection. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or that are portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-WNE antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-WNE antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis, prophylaxis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-WNE antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.